US Pharma MarketingAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2
Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar disorder, positioning its maker Autobahn Therapeutics to speed ahead to late-stage testing.
Source: FierceBiotech